394 related articles for article (PubMed ID: 22997170)
1. Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage.
Berry JL; Jubran R; Kim JW; Wong K; Bababeygy SR; Almarzouki H; Lee TC; Murphree AL
Pediatr Blood Cancer; 2013 Apr; 60(4):688-93. PubMed ID: 22997170
[TBL] [Abstract][Full Text] [Related]
2. Chemoreduction for group E retinoblastoma: comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in 76 eyes.
Shields CL; Ramasubramanian A; Thangappan A; Hartzell K; Leahey A; Meadows AT; Shields JA
Ophthalmology; 2009 Mar; 116(3):544-551.e1. PubMed ID: 19157557
[TBL] [Abstract][Full Text] [Related]
3. Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation.
Gündüz K; Günalp I; Yalçindağ N; Unal E; Taçyildiz N; Erden E; Geyik PO
Ophthalmology; 2004 Oct; 111(10):1917-24. PubMed ID: 15465557
[TBL] [Abstract][Full Text] [Related]
4. Factors predictive of long-term visual outcomes of Group D eyes treated with chemoreduction and low-dose IMRT salvage: the Children's Hospital Los Angeles experience.
Berry JL; Jubran R; Wong K; Lee TC; Murphree AL; Kim JW
Br J Ophthalmol; 2014 Aug; 98(8):1061-5. PubMed ID: 24671926
[TBL] [Abstract][Full Text] [Related]
5. Combined chemotherapy and local treatment in the management of intraocular retinoblastoma.
Brichard B; De Bruycker JJ; De Potter P; Neven B; Vermylen C; Cornu G
Med Pediatr Oncol; 2002 Jun; 38(6):411-5. PubMed ID: 11984802
[TBL] [Abstract][Full Text] [Related]
6. Management and outcome of retinoblastoma with vitreous seeds.
Manjandavida FP; Honavar SG; Reddy VA; Khanna R
Ophthalmology; 2014 Feb; 121(2):517-24. PubMed ID: 24572675
[TBL] [Abstract][Full Text] [Related]
7. Risk of metastasis and orbital recurrence in advanced retinoblastoma eyes treated with systemic chemoreduction versus primary enucleation.
Berry JL; Kogachi K; Aziz HA; McGovern K; Zolfaghari E; Murphree AL; Jubran R; Kim JW
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 28221729
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes of Group D retinoblastoma eyes during the intravitreal melphalan era.
Berry JL; Shah S; Bechtold M; Zolfaghari E; Jubran R; Kim JW
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28646513
[TBL] [Abstract][Full Text] [Related]
9. Chemoreduction for unilateral retinoblastoma.
Shields CL; Honavar SG; Meadows AT; Shields JA; Demirci H; Naduvilath TJ
Arch Ophthalmol; 2002 Dec; 120(12):1653-8. PubMed ID: 12470138
[TBL] [Abstract][Full Text] [Related]
10. Chemoreduction for retinoblastoma: analysis of tumor control and risks for recurrence in 457 tumors.
Shields CL; Mashayekhi A; Cater J; Shelil A; Meadows AT; Shields JA
Trans Am Ophthalmol Soc; 2004; 102():35-44; discussion 44-5. PubMed ID: 15747743
[TBL] [Abstract][Full Text] [Related]
11. The success of primary chemotherapy for group D heritable retinoblastoma.
Cohen VM; Kingston J; Hungerford JL
Br J Ophthalmol; 2009 Jul; 93(7):887-90. PubMed ID: 18703556
[TBL] [Abstract][Full Text] [Related]
12. Impact of chemoreduction for conservative therapy for retinoblastoma in Argentina.
Chantada GL; Fandiño AC; Schvartzman E; Raslawski E; Schaiquevich P; Manzitti J
Pediatr Blood Cancer; 2014 May; 61(5):821-6. PubMed ID: 24243706
[TBL] [Abstract][Full Text] [Related]
13. Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation.
Shields CL; Honavar SG; Meadows AT; Shields JA; Demirci H; Singh A; Friedman DL; Naduvilath TJ
Am J Ophthalmol; 2002 May; 133(5):657-64. PubMed ID: 11992863
[TBL] [Abstract][Full Text] [Related]
14. Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation.
Schefler AC; Cicciarelli N; Feuer W; Toledano S; Murray TG
Ophthalmology; 2007 Jan; 114(1):162-9. PubMed ID: 17070578
[TBL] [Abstract][Full Text] [Related]
15. Chemoreduction improves eye retention in patients with retinoblastoma: a report from the German Retinoblastoma Reference Centre.
Künkele A; Jurklies C; Wieland R; Lohmann D; Bornfeld N; Eggert A; Schulte JH
Br J Ophthalmol; 2013 Oct; 97(10):1277-83. PubMed ID: 23863458
[TBL] [Abstract][Full Text] [Related]
16. The outcome of chemoreduction treatment in patients with Reese-Ellsworth group V retinoblastoma.
Gündüz K; Shields CL; Shields JA; Meadows AT; Gross N; Cater J; Needle M
Arch Ophthalmol; 1998 Dec; 116(12):1613-7. PubMed ID: 9869790
[TBL] [Abstract][Full Text] [Related]
17. Macular retinoblastoma managed with chemoreduction: analysis of tumor control with or without adjuvant thermotherapy in 68 tumors.
Shields CL; Mashayekhi A; Cater J; Shelil A; Ness S; Meadows AT; Shields JA
Arch Ophthalmol; 2005 Jun; 123(6):765-73. PubMed ID: 15955977
[TBL] [Abstract][Full Text] [Related]
18. [Clinical therapeutic efficiency of chemoreduction and local therapy for children with retinoblastoma].
Qian J; Xue K; Gao YJ; Yuan YF; Shan HD; Bi YW
Zhonghua Yan Ke Za Zhi; 2010 Apr; 46(4):312-6. PubMed ID: 20654057
[TBL] [Abstract][Full Text] [Related]
19. Chemoreduction for intraocular retinoblastoma in Malaysia.
Menon BS; Juraida E; Alagaratnam J; Mohammad M; Ibrahim H; George TM; Ariffin H; Ho C; Khuzaiah R; Peng LH
J Pediatr Hematol Oncol; 2007 Jan; 29(1):2-4. PubMed ID: 17230058
[TBL] [Abstract][Full Text] [Related]
20. Iodine 125 plaque radiotherapy as salvage treatment for retinoblastoma recurrence after chemoreduction in 84 tumors.
Shields CL; Mashayekhi A; Sun H; Uysal Y; Friere J; Komarnicky L; Shields JA
Ophthalmology; 2006 Nov; 113(11):2087-92. PubMed ID: 16949158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]